Journal of pain & palliative care pharmacotherapy
-
J Pain Palliat Care Pharmacother · Jan 2011
Breakthrough cancer pain: mending the break in the continuum of care.
On February 23, 2010, the American Pain Foundation (APF), a nonprofit organization that promotes pain research and increased investments in pain research, hosted a roundtable discussion at Beth Israel Medical Center on cancer-related pain, with a specific focus on breakthrough cancer pain. This report summarizes discussions from that meeting, including recommendations and areas of consensus.
-
J Pain Palliat Care Pharmacother · Jan 2011
Declaration of Montréal: declaration that access to pain management is a fundamental human right.
At the conclusion of the 13th World Congress on Pain in Montreal, Quebec, Canada, the International Association for the Study of Pain (IASP) hosted an International Pain Summit on September 3, 2010, to address the tragedy of unrelieved pain in the world. At the conclusion of the Summit, the delegates adopted a Declaration that Access to Pain Management is a Fundamental Human Right. That Declaration is presented.
-
J Pain Palliat Care Pharmacother · Jan 2011
Food and Drug Administration recommends against the continued use of propoxyphene.
Following receipt of a Citizens' petition, the Food and Drug Administration (FDA) convened an advisory committee to address the safety of propoxyphene. This led to a comprehensive review that culminated in a November 19, 2910, press release in which the FDA recommended against continued use of the drug. The FDA release contains a data summary (background), a safety announcement, additional Information for Patients, additional information for health care professionals, and references. All dosage forms of the drug have now been withdrawn from the United States market.
-
Questions from patients about analgesic pharmacotherapy and responses from authors are presented to help educate patients and make them more effective self-advocates. The topic addressed in this query is ziconotide, a novel approach to the management of severe and chronic pain prepared from snail venom, its uses and possible side effects.
-
J Pain Palliat Care Pharmacother · Jan 2011
Opioid consumption in a tertiary hospital setting over an 8-year timeframe--a potential resource for tracking trends in pain management.
Opioid consumption by countries and health care organizations can be regarded as a marker of the quality of pain management. However, there are only limited data on opioid consumption in hospital settings. Objective and reliable data can be obtained by monitoring direct opioid consumption within a hospital, and then that data can be analyzed for identifying trends and directions to assist in guiding improved pain treatment within the hospital. This article tracks opioid consumption in a tertiary hospital over an 8-year period and by comparing the data to the consumption during the previous decade, it highlights trends and tendencies in the use of opioids as a potential indicator of pain management within this facility.